IDH-305 is primarily used in the field of oncology, specifically targeting cancers associated with mutations in the IDH1 gene. It functions as an inhibitor of the mutant IDH1 enzyme, which plays a role in the abnormal production of 2-hydroxyglutarate (2-HG), a metabolite that contributes to tumor growth. By blocking this enzyme, IDH-305 helps to normalize cellular metabolism and inhibit the progression of certain cancers, such as acute myeloid leukemia (AML) and cholangiocarcinoma. Its application is particularly significant in patients with IDH1-mutated tumors, offering a targeted therapeutic approach that can improve outcomes and reduce the side effects associated with conventional chemotherapy. Ongoing research continues to explore its potential in other IDH1-mutated cancers and combination therapies.